SCHEMBL832181

SCHEMBL832181

CCc1ccc2c(c1)c(-c1ccc[nH]c1=O)c(C(=O)NS(=O)(=O)C(C)C)n2Cc1cc(S(N)(=O)=O)ccc1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C8 P10632 1/20 0.38
KMT2A Q03164 5/20 0.33
MEN1 O00255 3/20 0.33
AGTR1 P30556 2/20 0.31
AGTR2 P50052 2/20 0.31
PPARG P37231 2/20 0.31
GFER P55789 1/20 0.31
PARG Q86W56 1/20 0.31
PDPK1 O15530 2/20 0.31
RORC P51449 2/20 0.30
TP53 P04637 1/20 0.30
MAPT P10636 1/20 0.30
L3MBTL1 Q9Y468 2/20 0.30
RXFP1 Q9HBX9 1/20 0.30
KDM4E B2RXH2 1/20 0.30
LMNA P02545 1/20 0.30
CA12 O43570 1/20 0.30
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
CA4 P22748 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL831226 0.91 CYP2C8 (0.40) CYP2C8KMT2AMEN1PPARGGFER
SCHEMBL831476 0.91 CYP2C8 (0.39) CYP2C8KMT2AMEN1AGTR1AGTR2
SCHEMBL830785 0.90 CYP2C8 (0.42) CYP2C8KMT2AMEN1AGTR1AGTR2
SCHEMBL831325 0.89 CYP2C8 (0.37) CYP2C8KMT2AMEN1PPARGPARG
SCHEMBL832522 0.89 PPARG (0.38) CYP2C8KMT2AAGTR1AGTR2PPARG
SCHEMBL12665388 0.88 CYP2C8 (0.48) CYP2C8KMT2AMEN1PPARGPARG
SCHEMBL832507 0.85 CYP2C8 (0.40) CYP2C8KMT2APPARGPARG
SCHEMBL831033 0.84 CYP2C8 (0.41) CYP2C8KMT2AMEN1AGTR1AGTR2
SCHEMBL831236 0.83 CYP2C8 (0.40) CYP2C8KMT2AMEN1AGTR1AGTR2
SCHEMBL831799 0.83 CYP2C8 (0.41) CYP2C8KMT2AMEN1AGTR1AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 CYP2C8 847/4885KMT2A 321/4885MEN1 2084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.